Cyclerion Therapeutics (Cyclerion Therapeutics) Total Stockholders Equity : $11.29 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Cyclerion Therapeutics Total Stockholders Equity?

Cyclerion Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $11.29 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Cyclerion Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $4.56. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Cyclerion Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.00.

Cyclerion Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Cyclerion Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclerion Therapeutics Total Stockholders Equity Chart

Cyclerion Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

97.73

59.49

48.25

10.45

11.29

Cyclerion Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial															10.45	3.93	5.15	12.87	11.29

Cyclerion Therapeutics (NAS:CYCN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Cyclerion Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(11.288	-	0)	/	2.47416
	=	4.56

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Cyclerion Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	11.288
	=	0.00

Cyclerion Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Cyclerion Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclerion Therapeutics (Cyclerion Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclerion Therapeutics Inc (NAS:CYCN) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 First Street, 18th Floor, Cambridge, MA, USA, 02142

Website

https://www.cyclerion.com

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

Executives

Terrance Mcguire	director	C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
Steven Hyman	director	C/O VOYAGER THERAPEUTICS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139
Andreas Busch	officer: Chief Scientific Officer	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
George H Conrades	director	500 TECHNOLOGY SQUARE, FIFTH FLOOR, CAMBRIDGE MA 02139
Stephanie Lovell	director	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Ole Isacson	director	CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Kevin Churchwell	director	C/O CYCLERION THERAPEUTICS, CAMBRIDGE MA 02142
Michael Mendelsohn	director	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Peter M Hecht	director, officer: Chief Executive Officer	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Slate Path Capital Lp	10 percent owner	717 5TH AVENUE, 16TH FL., NEW YORK NY 10022
Errol B Desouza	director	215 COLLEGE ROAD, PARAMUS NJ 07652
Anjeza Gjino	officer: Chief Financial Officer	C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Christopher I Wright	officer: Chief Medical Officer	C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Cheryl Gault	officer: Chief Operating Officer	CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Mark G Currie	officer: President and CSO	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142